No Data
No Data
Novo Nordisk Tops Quarterly Views, Tempers Full-Year Outlook
Super Micro, AMD, Marvell, Palantir, Disney, Uber, Novo, EA: Biggest Movers
Research Alert: CFRA Keeps Hold Opinion On Adss Of Novo Nordisk
UBS Group: Novo-Nordisk A/S (NVO.US) is under short-term pressure but this does not change its long-term value, maintaining a "Buy" rating.
UBS Group believes that Novo-Nordisk A/S's leading position in the treatment of diabetes and obesity, along with its strong R&D pipeline, gives it long-term investment value.
Novo Nordisk AS (NVO) Q1 2025 Earnings Call Highlights: Robust Growth Amid Challenges
Novo Nordisk Says Its 'Wegovy In A Pill' Delivers Big: '16.6% Average' Weight Loss, Over 20% For One-Third Of Adults Struggling With Obesity
SMG77 OP : sharp up and downs….![undefined [undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36)
28282828 : well setup trap
MIDORI REVIVER : very likely